Program 3: Cancer BiologyProgram (CBP)

计划 3:癌症生物学计划 (CBP)

基本信息

  • 批准号:
    9315740
  • 负责人:
  • 金额:
    $ 0.63万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-07-01 至 2021-06-30
  • 项目状态:
    已结题

项目摘要

Project Summary / Abstract: Cancer Biology Program (CBP) The goal of the Cancer Biology Program (CBP) is to identify etiologic mechanisms underlying cancer development and progression. As the main basic science of cancer platform for the University of Arizona Cancer Center, the Cancer Biology Program seeks to advance fundamental knowledge of the complex biological networks that are deranged in cancer and to characterize interactions between these complex biological networks and the environment that promote carcinogenesis and tumor progression. Translation of current findings and development of novel approaches to cancer prevention and treatment is facilitated through inter-programmatic collaborations and Cancer Center support. The program is organized into three major themes, including Genomic Instability and Epigenetic Control of Gene Expression, Signaling Networks in Carcinogenesis and Tumor Progression, and Invasion and Metastasis, with four aims: (i) to investigate mechanisms of cancer initiation and progression and to characterize cellular mechanisms that control cancer metastasis, (ii) to identify networks and regulatory pathways as potential markers or targets in prevention and treatment, (iii) to promote intra- and inter-programmatic collaborations to enhance translational research along the continuum from pre-clinical mouse models and human tissue correlates to clinical trials, and (iv) to foster research directions of particular relevance to individuals in Arizona and the Southwest. The Cancer Biology Program achieves these aims through establishment of working groups, conferences and seminars, and development of inter-disciplinary scientific teams; faculty recruitment, membership development and mentoring, and the use of developmental funds to spur targeted research; and, guidance and support of the shared resources. The CBP has 49 Members representing 21 different departments at the University of Arizona. CBP Members have published 390 cancer-relevant manuscripts, of which 30% were intra- programmatic and 36% were inter-programmatic. As of September 1, 2015, the CBP Program secured $11.8M total annual grant dollars with $2.5M from the NCI and $8.3M in other peer-reviewed funding. The CBP has regional impact through its members' basic research into the carcinogenic mechanisms of arsenicals that are pervasive environmental carcinogens in the Southwest. Finally, the Program is invested in using modern, high throughput genomic platforms to develop, enhance, and implement precision medicine. The expanding representation of Hispanic Americans in the State's population impels increased research into cancer health disparities in this population.
项目摘要/摘要:癌症生物学计划(CBP) 癌症生物学计划(CBP)的目标是确定癌症的病因机制 发展和进步。作为亚利桑那大学的主要癌症基础科学平台 癌症中心,癌症生物学计划旨在推进复杂的基础知识 这些复杂的生物网络之间的相互作用, 生物网络和环境,促进致癌和肿瘤进展。翻译 通过以下方式促进了癌症预防和治疗的新方法的当前发现和发展: 项目间合作和癌症中心支持。该计划分为三大部分 主题,包括基因组不稳定性和基因表达的表观遗传控制, 癌症发生和肿瘤进展,以及侵袭和转移,有四个目的:(i)研究 癌症发生和发展的机制,并表征控制癌症的细胞机制 转移,(ii)识别网络和调节途径作为预防中的潜在标志物或靶标, 治疗,(iii)促进项目内和项目间的合作,以加强转化研究,沿着 从临床前小鼠模型和人体组织的连续体与临床试验相关,以及(iv)培养 与亚利桑那州和西南部的个人特别相关的研究方向。癌症生物学 方案通过建立工作组、会议和研讨会实现这些目标, 跨学科科学团队的发展;教师招聘,会员发展和 指导,以及使用发展基金来刺激有针对性的研究;以及,指导和支持 共享资源。CBP有49名成员,分别代表香港大学21个不同的系。 亚利桑那CBP成员发表了390篇与癌症相关的手稿,其中30%是内部的, 36%是方案性的,36%是方案间的。截至2015年9月1日,CBP计划获得了1180万美元 年度总赠款美元,其中250万美元来自NCI,830万美元来自其他同行评审资金。CBP已经 通过其成员对砷剂致癌机制的基础研究, 在西南部普遍存在的环境致癌物。最后,该计划投资于使用现代化的,高 通过基因组平台来开发、增强和实施精准医疗。不断扩大的 西班牙裔美国人在该州人口中的代表性推动了对癌症健康的研究 这一人群中的差异。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nathan A. Ellis其他文献

106 Implication of the 3′Utr Region of TGFβR1 With MSS HNPCC and Sporadic Colorectal Cancer
  • DOI:
    10.1016/s0016-5085(13)60086-4
  • 发表时间:
    2013-05-01
  • 期刊:
  • 影响因子:
  • 作者:
    Rosa M Xicola;Brian J. Doyle;Jamie Rawson;Pilar Garre;Anna Abulí;Sathyaraj Murugappan;Ji Yeon Lee;Xavier Bessa;Juan Clofent;Luis Bujanda;Francesc Balaguer;Sergi Castellvi-Bel;Cristina Alenda;Rodrigo Jover;Clara Ruiz-Ponte;Sapna Syngal;Montserrat Andreu;Angel Carracedo;Antoni Castells;Nathan A. Ellis
  • 通讯作者:
    Nathan A. Ellis
Report of the Second International Workshop on Y Chromosome Mapping 1995.
1995 年第二届 Y 染色体作图国际研讨会报告。
  • DOI:
  • 发表时间:
    1994
  • 期刊:
  • 影响因子:
    0
  • 作者:
    N. Affara;Charles M. Bishop;William Brown;H. Cooke;Phillip M. Davey;Nathan A. Ellis;J. Graves;Michael H. Jones;Michael J. Mitchell;G. A. Rappold;C. Tyler;P. Yen;Yun
  • 通讯作者:
    Yun
The Xg blood group system: a review.
Xg 血型系统:回顾。
  • DOI:
    10.1016/s0887-7963(98)80001-1
  • 发表时间:
    1998
  • 期刊:
  • 影响因子:
    4.5
  • 作者:
    Patricia Tippett;Patricia Tippett;Nathan A. Ellis;Nathan A. Ellis
  • 通讯作者:
    Nathan A. Ellis
Erratum to Back mutation can produce phenotype reversion in Bloom syndrome somatic cells
  • DOI:
    10.1007/s004390100532
  • 发表时间:
    2001-05-23
  • 期刊:
  • 影响因子:
    3.600
  • 作者:
    Nathan A. Ellis;Susan Ciocci;James German
  • 通讯作者:
    James German
Ecce Ohno!
看,大野耐一!
  • DOI:
    10.1038/ng0895-373
  • 发表时间:
    1995-08-01
  • 期刊:
  • 影响因子:
    29.000
  • 作者:
    Nathan A. Ellis
  • 通讯作者:
    Nathan A. Ellis

Nathan A. Ellis的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nathan A. Ellis', 18)}}的其他基金

Epigenetic dysregulation in APC-negative colorectal cancer
APC 阴性结直肠癌的表观遗传失调
  • 批准号:
    10611424
  • 财政年份:
    2020
  • 资助金额:
    $ 0.63万
  • 项目类别:
Epigenetic dysregulation in APC-negative colorectal cancer
APC 阴性结直肠癌的表观遗传失调
  • 批准号:
    10400113
  • 财政年份:
    2020
  • 资助金额:
    $ 0.63万
  • 项目类别:
Epigenetic dysregulation in APC-negative colorectal cancer
APC 阴性结直肠癌的表观遗传失调
  • 批准号:
    10223247
  • 财政年份:
    2020
  • 资助金额:
    $ 0.63万
  • 项目类别:
Genomic/Genetic and Proteome
基因组/遗传学和蛋白质组
  • 批准号:
    10871778
  • 财政年份:
    2016
  • 资助金额:
    $ 0.63万
  • 项目类别:
Regulation of Homologous Recombination in Human Cells
人类细胞同源重组的调控
  • 批准号:
    8449497
  • 财政年份:
    2011
  • 资助金额:
    $ 0.63万
  • 项目类别:
Regulation of Homologous Recombination in Human Cells
人类细胞同源重组的调控
  • 批准号:
    8041273
  • 财政年份:
    2011
  • 资助金额:
    $ 0.63万
  • 项目类别:
Regulation of Homologous Recombination in Human Cells
人类细胞同源重组的调控
  • 批准号:
    8906781
  • 财政年份:
    2011
  • 资助金额:
    $ 0.63万
  • 项目类别:
Regulation of Homologous Recombination in Human Cells
人类细胞同源重组的调控
  • 批准号:
    8268383
  • 财政年份:
    2011
  • 资助金额:
    $ 0.63万
  • 项目类别:
Genetic risk factors in African American colorectal cancer patients
非裔美国结直肠癌患者的遗传危险因素
  • 批准号:
    8705888
  • 财政年份:
    2010
  • 资助金额:
    $ 0.63万
  • 项目类别:
Genetic risk factors in African American colorectal cancer patients
非裔美国结直肠癌患者的遗传危险因素
  • 批准号:
    8545719
  • 财政年份:
    2010
  • 资助金额:
    $ 0.63万
  • 项目类别:

相似海外基金

ADVANCED DEVELOPMENT OF LQ A LIPOSOME-BASED SAPONIN-CONTAINING ADJUVANT FOR USE IN PANSARBECOVIRUS VACCINES
用于 Pansarbecovirus 疫苗的 LQ A 脂质体含皂苷佐剂的先进开发
  • 批准号:
    10935820
  • 财政年份:
    2023
  • 资助金额:
    $ 0.63万
  • 项目类别:
ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"
BBT-059 的先进开发,作为辐射医学对策,可在暴露后 48 小时内进行给药”
  • 批准号:
    10932514
  • 财政年份:
    2023
  • 资助金额:
    $ 0.63万
  • 项目类别:
Advanced Development of a Combined Shigella-ETEC Vaccine
志贺氏菌-ETEC 联合疫苗的先进开发
  • 批准号:
    10704845
  • 财政年份:
    2023
  • 资助金额:
    $ 0.63万
  • 项目类别:
Advanced development of composite gene delivery and CAR engineering systems
复合基因递送和CAR工程系统的先进开发
  • 批准号:
    10709085
  • 财政年份:
    2023
  • 资助金额:
    $ 0.63万
  • 项目类别:
Advanced Development of Gemini-DHAP
Gemini-DHAP的高级开发
  • 批准号:
    10760050
  • 财政年份:
    2023
  • 资助金额:
    $ 0.63万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10409385
  • 财政年份:
    2022
  • 资助金额:
    $ 0.63万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10710595
  • 财政年份:
    2022
  • 资助金额:
    $ 0.63万
  • 项目类别:
Advanced development and validation of an in vitro platform to phenotype brain metastatic tumor cells using artificial intelligence
使用人工智能对脑转移肿瘤细胞进行表型分析的体外平台的高级开发和验证
  • 批准号:
    10630975
  • 财政年份:
    2022
  • 资助金额:
    $ 0.63万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE CANDIDATE FOR STAPHYLOCOCCUS AUREUS INFECTION
金黄色葡萄球菌感染候选疫苗的高级开发
  • 批准号:
    10710588
  • 财政年份:
    2022
  • 资助金额:
    $ 0.63万
  • 项目类别:
ADVANCED DEVELOPMENT OF A VACCINE FOR PANDEMIC AND PRE-EMERGENT CORONAVIRUSES
针对大流行和突发冠状病毒的疫苗的高级开发
  • 批准号:
    10788051
  • 财政年份:
    2022
  • 资助金额:
    $ 0.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了